Ras

Cat. No.

A63573

CAS No.

2972625-49-1

KRAS G12D inhibitor 26

KRAS G12D inhibitor 26 is a specific inhibitor targeting the KRAS(G12D) mutation, with an IC50 of ≤ 100 nM. This compound modulates KRAS signaling pathways, making it a valuable tool for studying KRAS-related oncogenic processes. Its application is pivotal in cancer research, particularly in elucidating the mechanisms underlying tumorigenesis and therapeutic resistance in KRAS-driven malignancies.

Cat. No.

A63574

CAS No.

306969-25-5

p67phox-IN-1

p67phox-IN-1 is a specific inhibitor of the interaction between Rac GTPase and the p67phox protein. This compound interferes with the activation of the NADPH oxidase complex, thereby modulating reactive oxygen species production. p67phox-IN-1 serves as a valuable tool in research related to oxidative stress, inflammation, and redox signaling pathways. Its utility extends to studies exploring the role of Rac GTPases in various physiological and pathological processes.

Cat. No.

A63575

CAS No.

2070916-70-8

PPI-GIT1/β-Pix PPI-IN-1

PPI-GIT1/β-Pix PPI-IN-1 is a potent inhibitor of the GIT1/β-Pix protein-protein interaction, exhibiting a KD value of 7.7 µM. By disrupting the GIT/PIX interaction, this compound effectively modulates the activation of downstream Rho GTPases Rac1 and Cdc42, which are critical in various signaling pathways. PPI-GIT1/β-Pix PPI-IN-1 is particularly relevant in cancer research, demonstrating significant inhibitory effects on the metastasis of gastric cancer.

Cat. No.

A63577

CAS No.

2621928-43-4

KRAS G12D inhibitor 1

KRAS G12D Inhibitor 1 is a potent inhibitor targeting the KRAS G12D mutant with an IC50 of 0.4 nM. It effectively inhibits KRAS G12D-mediated ERK phosphorylation, exhibiting an IC50 of 0.8 nM. This compound is valuable in research focused on cancers driven by KRAS G12D mutations, including pancreatic ductal adenocarcinoma and colorectal cancer.

Cat. No.

A63579

CAS No.

3081520-70-6

(R)-KRAS G12D inhibitor 28 hydrochloride dihydrate

(R)-KRAS G12D inhibitor 28 hydrochloride dihydrate specifically targets the KRAS G12D mutant protein, functioning as an effective inhibitor. This compound demonstrates significant potential in cancer research, particularly in studies focused on KRAS-driven malignancies. Its application can aid in the investigation of KRAS signaling pathways and the development of targeted therapies for KRAS-related tumors.

Cat. No.

A63580

CAS No.

2409131-50-4

KRASG12C IN-13

KRASG12C IN-13 is a selective inhibitor targeting the KRAS G12C mutation. This compound demonstrates significant biological activity against advanced solid tumors, particularly non-small cell lung cancer and colorectal cancer. Researchers can utilize KRASG12C IN-13 to investigate therapeutic strategies and resistance mechanisms associated with KRAS-driven malignancies.

Cat. No.

A63581

CAS No.

2042365-85-3

Kras4B G12D-IN-1

Kras4B G12D-IN-1 is a selective inhibitor of the Kras4B G12D mutant, targeting its oncogenic activity. This compound demonstrates significant anticancer properties by reducing Kras protein expression in mouse embryonic fibroblasts (MEF) harboring the Kras4B G12D mutation. Kras4B G12D-IN-1 is relevant for research investigating Kras-driven cancers and the development of targeted therapies.

Cat. No.

A63582

CAS No.

3033638-63-7

KRASG12D-IN-3

KRASG12D-IN-3 is a potent inhibitor that specifically targets the KRASG12D mutation. It demonstrates significant anti-proliferative effects on AGS and AsPC-1 cell lines, with IC50 values of 0.38 nM and 1.23 nM, respectively. This compound is valuable for research applications focused on the role of KRAS mutations in cancer biology and therapeutic development.

Cat. No.

A63585

CAS No.

3105153-34-9

IACS-56676

IACS-56676 is a selective inhibitor of the NRAS G12D mutation, with a binding affinity (Kd) of 0.031 μM. It stabilizes the p-loop and preserves critical interactions with key residues, including Asp12, Gly60, and Asp69, allowing for its specificity toward NRAS G12D while sparing wild-type KRAS through targeting Leu95. This compound is applicable in research focusing on melanoma, hematologic malignancies, and thyroid cancer, providing a valuable tool for investigating targeted therapies in these contexts.

Cat. No.

A63586

CAS No.

2893809-52-2

(4R)-BBO-8520

(4R)-BBO-8520 is a selective inhibitor of the KRAS G12C mutant. This compound effectively impedes the KRAS G12C (ON) signaling, thereby inhibiting cell proliferation by blocking the interaction with GTP. Additionally, (4R)-BBO-8520 disrupts the RAS-RAF1 interaction, facilitating the return of KRAS G12C to its inactive (OFF) state. It is particularly valuable for research applications focused on cancer biology and therapeutics targeting KRAS-driven malignancies.

Cat. No.

A63588

CAS No.

24527-27-3

Spiclomazine

Synonyms: Clospirazine

Spiclomazine is a selective inhibitor of mutant KRAS(G12C), targeting KRAS-driven pancreatic cancer. This compound effectively reduces KRas-GTP levels and inhibits downstream RAS-mediated signaling pathways. In preclinical studies, Spiclomazine demonstrates significant tumor progression inhibition in mouse renal capsule xenotransplantation models, making it a valuable tool for researching therapeutic strategies against KRAS-driven malignancies.

Cat. No.

A63593

CAS No.

3044773-77-2

K-Ras-IN-4

K-Ras-IN-4 is a potent K-Ras inhibitor that specifically targets the K-Ras oncogene, a critical player in cancer cell signaling. This compound effectively impedes K-Ras-mediated signaling pathways, thereby attenuating cell proliferation and survival in K-Ras-driven tumors. K-Ras-IN-4 is utilized in research focused on understanding K-Ras biology and developing targeted therapies for cancers associated with K-Ras mutations.

Cat. No.

A63594

CAS No.

2648551-54-4

KRAS G12D inhibitor 10

KRAS G12D Inhibitor 10 is a selective inhibitor targeting the KRAS G12D mutation, a critical driver in various cancers. By inhibiting this variant, the compound demonstrates significant potential for research applications focused on KRAS G12D-mediated oncogenesis. Its role in disrupting the Ras signaling pathway makes it valuable for studies investigating cancer growth and therapeutic resistance mechanisms.

Cat. No.

A63595

CAS No.

2244904-69-4

(S)-BAY-293

(S)-BAY-293 serves as a negative control for the potent KRAS-SOS1 interaction inhibitor, BAY 293. This compound is utilized in experimental settings to validate the specificity and efficacy of BAY 293 in studying KRAS signaling pathways. Researchers can use (S)-BAY-293 to ensure experimental results are due to the intended inhibition and not off-target effects.

Cat. No.

A63597

CAS No.

2022986-61-2

KRAS inhibitor-6

KRAS inhibitor-6 is a potent inhibitor of the KRAS G12C mutation, specifically designed to selectively target and inhibit this oncogenic driver. Its mechanism of action involves binding to the active site of the mutant KRAS protein, effectively disrupting downstream signaling pathways involved in cellular proliferation and survival. This compound has significant implications for cancer research and therapeutic applications, particularly in the treatment of KRAS-driven tumors.

Cat. No.

A63598

CAS No.

2022986-70-3

KRAS inhibitor-8

KRAS inhibitor-8 is a selective inhibitor targeting the KRAS G12C mutation, known for its role in various cancers. This compound demonstrates significant biological activity by effectively disrupting KRAS signaling pathways, leading to reduced tumor growth in KRAS-driven malignancies. KRAS inhibitor-8 is ideal for research in cancer biology and drug discovery focused on mutant KRAS therapeutics.

Cat. No.

A63599

CAS No.

2022986-68-9

KRAS inhibitor-7

KRAS inhibitor-7 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound demonstrates significant inhibition of KRAS G12C activity, making it a valuable tool for studying oncogenic signaling pathways involving KRAS mutations. Its primary applications include cancer research, particularly in the development of targeted therapies for KRAS-driven tumors.

Cat. No.

A63600

CAS No.

2642630-16-6

KRAS mutant protein inhibitor 1

KRAS mutant protein inhibitor 1 selectively targets and inhibits the activity of mutant KRAS proteins. Its primary mechanism involves disruption of KRAS-mediated signaling pathways, which are critical in various cancers. This compound is valuable for research applications focused on understanding the role of KRAS mutations in tumorigenesis and exploring potential therapeutic strategies for KRAS-driven malignancies.

Cat. No.

A63601

CAS No.

2756739-00-9

KRAS G12C inhibitor 32

KRAS G12C Inhibitor 32 is a potent inhibitor targeting the KRAS G12C mutation. This eight-membered heterocyclic compound demonstrates strong inhibitory activity, which is critical for studies focusing on cancer therapeutics associated with KRAS mutations. It is primarily utilized in research exploring the mechanisms of KRAS-driven malignancies and the development of targeted therapies.

Cat. No.

A63603

CAS No.

2648584-51-2

KRAS G12C inhibitor 27

KRAS G12C inhibitor 27 is a potent inhibitor targeting the KRAS G12C mutant protein, which plays a pivotal role in various cancers. This compound exhibits significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic development. Its application extends to studying KRAS-driven tumors and evaluating the efficacy of targeted therapies.

Cat. No.

A63605

CAS No.

2757095-11-5

KRAS G12D inhibitor 3

KRAS G12D inhibitor 3 is a selective inhibitor targeting the KRAS G12D mutant with an IC50 of less than 500 nM. It exhibits significant antitumor activity, making it relevant for cancer research focused on KRAS-driven tumors. Additionally, this compound functions as a click chemistry reagent, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition with azide-containing molecules, facilitating various bioconjugation applications in molecular biology.

Cat. No.

A63606

CAS No.

2946593-43-5

G12Si-2

G12Si-2 is an analog of G12Si-1 that serves as a negative control in research applications. It acts as a non-covalent inhibitor specifically for the G12S mutant of K-Ras. This compound is valuable for studies aimed at elucidating the mechanisms of K-Ras signaling and evaluating the effects of various inhibitors in cellular contexts.

Cat. No.

A63607

CAS No.

2649788-45-2

KRAS G12C inhibitor 18

KRAS G12C inhibitor 18 is a selective inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anti-tumor activity, making it valuable for cancer research focused on KRAS-driven malignancies. It is suitable for studies investigating the therapeutic potential of KRAS inhibition in oncogenesis and treatment resistance.

Cat. No.

A63608

CAS No.

2411786-32-6

KRAS inhibitor-20

KRAS Inhibitor-20 is a small molecule inhibitor targeting the oncogenic mutant KRasG12C. It demonstrates potent inhibitory activity with an IC50 value of less than 10 nM, making it an effective tool for studying KRas-driven malignancies. This compound is valuable for research applications focused on cancer biology, offering insights into therapeutic strategies for KRas-related tumors.

Cat. No.

A63609

CAS No.

2230873-67-1

KRAS inhibitor-16

KRAS Inhibitor-16 is a selective inhibitor targeting the KRAS G12C mutation, demonstrating a potent activity with an IC50 of 0.457 µM. This compound effectively inhibits phosphorylated ERK in MIA PaCA-2 and A549 cell lines, with IC50 values of 3.06 µM and 11.1 µM, respectively. KRAS Inhibitor-16 is suitable for research applications focusing on pancreatic, colorectal, and lung cancers, contributing to the advancement of targeted therapies in these malignancies.